The document summarizes the recommendations of the 2014 JNC 8 guidelines for treatment of hypertension. It discusses:
1) The JNC 8 recommendation to initiate pharmacologic treatment for those aged 60 and older with a systolic blood pressure of 150 mm Hg or higher, and to treat to a goal of under 150 mm Hg.
2) Evidence from trials supporting this recommendation showing reduced risks of stroke, heart failure, and coronary heart disease with treatment to a goal of under 150 mm Hg.
3) Arguments against recommending treatment to lower goals not proven in clinical trials, such as unnecessary exposure to medication side effects and polypharmacy in the elderly.
European Society of Hypertension 2013 Hypertension guidelines presentation in...JAFAR ALSAID
Summary of the European Society of Hypertension 2013 Hypertension Guidelines presented during the Eighth Hypertension and Cardiovascular highlight session in Bahrain on Sept. 11th 2013.
The goal of this webinar is to educate physicians and healthcare professionals about hospice eligibility and benefits for patients with advanced cardiac disease (ACD) who have a prognosis of ≤6 months. Through evidence-based data and a review of case studies, attendees understand the benefits of advance care planning, complex modalities for high-acuity cardiac patients, how to manage symptoms, address pain and provide comfort and dignity near the end of life.
Heart failure is the leading cause of death in the US, yet accounts for less than 20 percent of hospice admissions. The goal of this webinar is to teach healthcare professionals to recognize what were once routine and manageable exacerbations as signs of unstable terminal illness, and to understand why hospice improves quality of life when proven treatments no longer can can.
Prevention of recurrent stroke in atrial fibrillation Jacek StaszewskiJacek Staszewski
Prevention of recurrent stroke in atrial fibrillation. Comaprison of NOAC vs VKA. Riks of hemorrhagic stroke. When anticoagulation should be initiated following acute stroke.
European Society of Hypertension 2013 Hypertension guidelines presentation in...JAFAR ALSAID
Summary of the European Society of Hypertension 2013 Hypertension Guidelines presented during the Eighth Hypertension and Cardiovascular highlight session in Bahrain on Sept. 11th 2013.
The goal of this webinar is to educate physicians and healthcare professionals about hospice eligibility and benefits for patients with advanced cardiac disease (ACD) who have a prognosis of ≤6 months. Through evidence-based data and a review of case studies, attendees understand the benefits of advance care planning, complex modalities for high-acuity cardiac patients, how to manage symptoms, address pain and provide comfort and dignity near the end of life.
Heart failure is the leading cause of death in the US, yet accounts for less than 20 percent of hospice admissions. The goal of this webinar is to teach healthcare professionals to recognize what were once routine and manageable exacerbations as signs of unstable terminal illness, and to understand why hospice improves quality of life when proven treatments no longer can can.
Prevention of recurrent stroke in atrial fibrillation Jacek StaszewskiJacek Staszewski
Prevention of recurrent stroke in atrial fibrillation. Comaprison of NOAC vs VKA. Riks of hemorrhagic stroke. When anticoagulation should be initiated following acute stroke.
Blood Pressure Targets 2017.Still Struggling for the Right Answermagdy elmasry
Blood Pressure Targets 2017.Guidelines For Hypertension 2011-2015.Does SPRINT change our approach to BP targets?
SPRINT vs. ACCORD.Updated Hypertension Guidelines Released by ACP, AAFP
QA Paediatric dentistry department, Hospital Melaka 2020Azreen Aj
QA study - To improve the 6th monthly recall rate post-comprehensive dental treatment under general anaesthesia in paediatric dentistry department, Hospital Melaka
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
Welcome to Secret Tantric, London’s finest VIP Massage agency. Since we first opened our doors, we have provided the ultimate erotic massage experience to innumerable clients, each one searching for the very best sensual massage in London. We come by this reputation honestly with a dynamic team of the city’s most beautiful masseuses.
Telehealth Psychology Building Trust with Clients.pptxThe Harvest Clinic
Telehealth psychology is a digital approach that offers psychological services and mental health care to clients remotely, using technologies like video conferencing, phone calls, text messaging, and mobile apps for communication.
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
Navigating the Health Insurance Market_ Understanding Trends and Options.pdfEnterprise Wired
From navigating policy options to staying informed about industry trends, this comprehensive guide explores everything you need to know about the health insurance market.
Dehradun ❤CALL Girls 8901183002 ❤ℂall Girls IN Dehradun ESCORT SERVICE❤
Debate evidence bases guideline handler
1. Joel Handler, MD
Southern Cal Kaiser Permanente
Hypertension Lead
Southern California Permanente Group
JNC 8: They Got it Right
Joint NationJlJ COmmittee
3. Joint National Committee on
Prevention, Detection,
Evaluation, & Treatment of High
Blood Pressure (JNC)
JNC 7: 2003
JNC 6: 1997
JNC 5: 1992
JNC 4: 1988
JNC 3: 1984
JNC 2: 1980
JNC 1: 1976
Detection, Evaluation, &
Treatment of High Blood
Cholesterol in Adults (ATP, Adult
Treatment Panel)
ATP III Update: 2004
ATP III: 2002
ATP II: 1993
ATP I: 1988
Clinical Guidelines on the
Identification, Evaluation, &
Treatment of Overweight and
Obesity in Adults
Obesity 1: 1998
3
History of
NHLBI CVD Adult Clinical Guidelines
4. NHLBI Study Assessment Tool:
Controlled Intervention Studies
Criteria Yes No Other
1.Was the study described as randomized, a randomized trial, a randomized clinical
trial, or an RCT?
5. Were the people assessing the outcomes blinded to the participants’ group
assignments?
7. Was the overall drop-out rate from the study at its endpoint 20% or less than the
number originally allocated to treatment?
14. Were all randomized participants analyzed in the group to which they were
originally assigned (i.e., did they use an intention-to-treat analysis)?
Quality Rating (Good, Fair, Poor) (see guidance)
Rater #1 initials: Rater #2 initials:
Additional Comments (If POOR, please state why):
5. Articles Screened = 1978
Good = 17
Included = 92
Total Abstracted = 56
Excluded = 1886
(Did not meet
prespecified
inclusion criteria)Poor = 36Fair = 39
Question 2: Among adults, does treatment with antihypertensive
pharmacological therapy to a specified BP goal lead to improvements
in health outcomes?
6. NHLBI Systematic Review and
Guideline Development Process
Literature Searched;
All Eligible Studies
Identified
Studies Quality Rated;
Evidence Tables
Developed
Evidence
Summarized;
Graded by Panel
w/ Methodologists
Resources
Obtained;
Expert Panel
Established
Topic Area
Identified
Critical Questions,
Study Eligibility
Criteria Identified
Draft Reports
Written, Reviewed,
Revised
Reports
Disseminated &
Implemented
Recommendations
Developed and Graded
By Panel
*The Blue portion is the Systematic Review
7.
8. In the general adult population 60 years
of age and older, initiate pharmacologic
treatment to lower blood pressure at SBP
≥ 150mm Hg or DBP ≥ 90mm Hg and treat
to a goal SBP <150 mm Hg and goal DBP
<90mmHg.
(Strong Recommendation – Grade A)
Recommendation
9. Corollary : In the general population 60 years
of age and older, if pharmacologic treatment
for high blood pressure results in a lower
achieved SBP (for example, less than 140
mmHg) and treatment is well tolerated without
adverse effects on health or quality of life,
treatment does not need to be adjusted
Expert opinion
Recommendation
11. JNC 8 Misrepresentation
• JNC 8 did not base it’s SBP 150
recommendation on JATOS and
VALISH
• SHEP, SystEur, and HYVET were
highly rated studies
• Only HYVET randomized age 80
and over
14. Evidence Quality
Type Of Evidence Quality
Rating
Well-designed, well executed RCTs that adequately
represent populations to which the results are
applied and directly assess effects on health
outcomes
High
15.
16. The absence of
The absence of evidence for
a goal SBP lower than other
than < 150 mmHg does NOT
equal evidence.
17. Why Not Use Achieved Blood
Pressures?
•Mean achieved BPs are not Goal BPs
•Post Hoc Analyses of patients achieving
lower BPs tend to identify those at lower
risk: less LVH, lower baseline BPs, fewer
meds, improved med adherence
18.
19. Cochrane Database of Systematic Reviews:
Treatment Blood Pressure Targets for
Hypertension 2009
“The cohort of patients with low blood
pressure as identified by achieved blood
pressure selects for patients who did not
have sustained elevated blood pressure in
the first place, for patients in whom the blood
pressure is most easily reduced, for patients
with the lowest baseline blood pressure, and
for patients who are most compliant (healthy
user effect, Dormuth 2009).”
continued …
20. Cochrane 2009 continued
“All of these factors are most
likely associated with a lower risk
of having an adverse
cardiovascular event. The
approach is thus heavily biased for
finding less cardiovascular events
in the patients with lower blood
pressure.”
Arguedas JA, Perez MI, Wright JM
21. Which clinical trials + meta-analyses were
excluded because of excessive bias?
• FEVER
• PREVENT
• BP Lowering Treatment
Trialists’ Collaboration
22. Recommendation 1:
In the general adult population 60 years of age and
older, initiate pharmacologic treatment to lower blood
pressure at SBP ≥150 mm Hg or DBP ≥90 mm Hg and
treat to a goal SBP <150 mm Hg and goal DBP <90
mm Hg.
(Strong Recommendation - Grade A)
• Motion voted on during February 27-28 face-to-face
meeting: move forward with recommendation as is,
but include a ‘thoughtful’ discussion of the
epidemiological data and other consideration in the
narrative
• 15 in favor, 2 against
23. EVIDENCE STATEMENTS FOR QUESTION 2 CONTRIBUTING TO RECOMMENDATION 1
Question 2: Among adults, does treatment with antihypertensive pharmacological
therapy to a specified BP goal lead to improvements in health outcomes?
Evidence Statement 1: Treatment with antihypertensive medication to lower SBP in
adults 60 years of age or older to a goal systolic BP <150 mm Hg reduces
cerebrovascular morbidity and mortality (includes fatal stroke, nonfatal stroke or a
combination of fatal and nonfatal stroke).
Vote: Agree with the statement (17/17); Evidence Quality: High (15/17),
Moderate (2/17)
Evidence Statement 2: Treatment with antihypertensive medication to lower
SBP in adults 60 years of age or older to a goal systolic BP <150 mm Hg reduces
fatal and nonfatal heart failure.
Vote: Agree with the statement (17/17); Evidence Quality: Moderate (15/17),
High (2/17)
Evidence Statement 3: Treatment with antihypertensive medication to lower
SBP in adults 60 years of age or older to a goal systolic BP <150 mm Hg
reduces coronary heart disease (includes non-fatal MI, fatal MI, CHD death, or
sudden death).
Vote: Agree with the statement (17/17); Evidence Quality: Moderate (17/17)
24.
25.
26. Will a higher SBP goal facilitate therapeutic
inertia?
“Clinical inertia has to be fought by
other means than by recommending
inappropriately low BP targets.”
Mancia G, Fagard R. J Hypertension
2013; 31: 2462-2465
29. Why is it important not to recommend intensifying
medication to reduce BP below the level proven in
clinical trials?
• Exposure to side effects of unnecessary
medications and excessive doses
• Polypharmacy in the elderly
• Reduced medication adherence
• Possibly an increase in serious falls
• Possibly a J- or U- curve increase in CV risk
• Unnecessary use of limited health care
resources